Jessie Lin

Jessie is a multidisciplinary leader with 15 years of experience across the life sciences industry, specializing in strategic growth initiatives and corporate communications. She joined Nuvalent full time in September 2021 after working closely with the company through its emergence from stealth, Series B financing, and upsized IPO.

Most recently, Jessie was Director, Strategic Planning & Communications at Verastem Oncology. In this role, she led transformative business development, regulatory, and patient advocacy initiatives which enabled the pivot from an early-stage biotech to a commercial stage oncology company with an FDA approved product in just 3 years. Following the FDA approval of COPIKTRA®, Jessie served as alliance manager for development and commercialization collaborations in China and Japan.

Jessie earned her bachelor’s degree in bioengineering as a member of the founding four classes at the Franklin W. Olin College of Engineering.